📚 See the Olive Young, PharmaResearch and K-Beauty investment hub for the full thread across Rejuran / PharmaResearch, Olive Young, CJ and APR / Medicube.

TL;DR

• Rejuran is owned by PharmaResearch Co., Ltd. (KOSDAQ: 214450), a Korean medical-aesthetics specialty company. Rejuran is a brand; the underlying technology is PharmaResearch’s proprietary PN (Polynucleotide) / PDRN platform, derived from purified salmon DNA fragments.
• PharmaResearch is the only listed public proxy for the polynucleotide skin-booster category. There is no separate Rejuran ticker — buying Rejuran exposure means buying PharmaResearch.
• The Rejuran franchise is now multi-product, multi-indication, multi-region: Rejuran Healer / HB / Eye / S, distributed across 50+ countries with active expansion in Thailand, Indonesia, Vietnam, Malaysia, the Middle East, Brazil, and the EU. China and US entry are the high-value pending catalysts.
• Competitive frame: Rejuran is not a botulinum toxin (Hugel, Medytox, Daewoong) and not a hyaluronic-acid filler (Galderma Restylane, AbbVie Juvederm). It defines its own subcategory — regenerative skin-booster via salmon-DNA polynucleotide — and sits closer to Galderma’s Sunekos / Croma’s pipeline in Western markets.
• Investor framing: PharmaResearch is a specialty-platform compounder with a single-flagship-brand concentration risk. Bulls focus on PN-platform extensibility and ex-Korea growth runway. Bears focus on competitive entrants (Korean and Western) and pricing pressure as the polynucleotide category gets crowded.

1. The Direct Answer

Rejuran is manufactured, marketed, and licensed globally by PharmaResearch Co., Ltd. (KOSDAQ: 214450).

Important framing: search-engine queries like “who owns rejuran” and “rejuran parent company” land here because Rejuran has stronger consumer brand recognition (especially in Southeast Asia and the Middle East) than the company that makes it. Most clinic patients and end consumers know “Rejuran” but not “PharmaResearch.”

For investors, the relevant identity is the parent. PharmaResearch is the public ticker; Rejuran is its flagship product brand.

2. The Platform Behind the Brand: PN / PDRN from Salmon DNA

What Rejuran actually is, technically:

• PDRN = Polydeoxyribonucleotide. PN = Polynucleotide. Both refer to fragmented DNA polymers.
• Rejuran’s active ingredient is purified, fragmented salmon DNA polynucleotides processed to a defined molecular-weight range.
• Mechanism (publicly stated by the company and dermatology literature): polynucleotides are believed to act as substrates for adenosine A2A receptors, promote fibroblast activity, modulate inflammation, and support collagen / elastin synthesis at the dermal layer.
• Clinical positioning: regenerative skin booster (not a filler that adds volume; not a neurotoxin that paralyzes muscle). Used for skin-quality improvement — texture, fine lines, hydration, scars, post-acne, peri-orbital area.

The strategic implication for investors:

• PharmaResearch is vertically integrated on the PN platform — raw material handling, purification, formulation, sterile injectable manufacturing, regulatory dossiers, brand marketing, clinical-channel education.
• The platform is extensible. Rejuran for face is one application. Conjuran for joints is another. Future indications (hair, scalp, post-procedural recovery, scar, surgical wound) sit on the same upstream chemistry.
• Brand vs. ingredient is the value-capture question. PDRN as a category exists outside PharmaResearch — Italian companies (Mastelli’s “PDRN” formulations) and other entrants exist. What PharmaResearch owns is Rejuran as a brand-trust asset and the manufacturing-quality-system reputation that has made Rejuran the defining brand in Korea, Southeast Asia, and parts of MENA.

3. The Rejuran Product Family

A practical map for global readers who encounter Rejuran in clinics:

In some markets, additional SKUs and bundles exist via local distributors. The brand also extends into dermo-cosmetic / cosmeceutical lines (e.g., Rejuran Healer Skin Care series in select markets), which are non-injectable home-use products under brand license.

For investor due diligence: revenue mix between Rejuran (face) / Conjuran (joint) / cosmeceutical / device & other has historically been weighted heavily toward Rejuran (face), with Conjuran and cosmeceutical as growth optionality.

4. PharmaResearch as the Only Listed Public Proxy

Investors looking for Rejuran exposure have one and only one listed entry point: PharmaResearch (214450.KS / KOSDAQ).

What you get when you own PharmaResearch:

Why no separate Rejuran ticker exists:

PharmaResearch has historically chosen to keep Rejuran inside the parent company rather than spin it out. The advantage for the parent: Rejuran is the cash-generative flagship, and consolidating its margin inside PharmaResearch’s P&L underwrites the company’s overall growth story. A spinout has been speculated periodically, but as of April 2026 there is no public announcement of such a transaction.

General financial-profile shape (industry-tracked levels, directional):

• Revenue growth: high-teens to high-20s % YoY range across multiple recent years, driven by Rejuran international plus Conjuran ramp.
• Operating margin: high-teens to mid-20s % range — characteristic of a specialty-injectable manufacturer with strong brand pricing power and modest sales-and-marketing intensity (clinic-channel pull rather than mass-media push).
• Dividend: modest payout; growth-stage capital allocation has prioritized capacity, R&D, and selective overseas-market investment over yield.
• Cash position: net cash historically; capex weight has stepped up alongside international expansion.

(Specific quarterly revenue, OPM, and net-cash levels should be cross-checked against the company’s most recent disclosure on DART or its investor-relations site before any sizing decision.)

5. Global Expansion — Where Rejuran Is Actually Selling

The most underappreciated piece of the Rejuran story for non-Korean investors is how international the franchise has already become.

Active commercial markets (illustrative; via local distributors and clinic-channel adoption):

• Southeast Asia — Thailand, Singapore, Malaysia, Indonesia, Vietnam, Philippines. Thailand has been a particular standout, with strong clinic-channel adoption and high consumer brand awareness.
• Middle East / Gulf — UAE, Saudi Arabia (regulatory pathway by emirate / authority), with Dubai and Riyadh aesthetic clinics being early adopters.
• South Asia — India (regulatory entry).
• Australia / NZ — selected clinic networks.
• Latin America — Brazil (the largest medical-aesthetics market in LatAm), Mexico.
• Europe — selected EU markets via CE-marked formulations.
• Russia / CIS — historically active, with current dynamics affected by macro / sanctions environment.

Pending high-value catalysts:

• China — the single biggest pending catalyst. The Chinese medical-aesthetics market is the largest ex-US opportunity and would be transformational for any polynucleotide-platform owner if formal NMPA pathways open broadly to imported PN injectables. Local dynamics include parallel imports, daigou (personal-import) flows, and regulatory tightening cycles. PharmaResearch has pursued formal entry; the timing and final approval scope remain partially uncertain.
• United States — the highest-value but most regulatory-intense pathway. The US FDA pathway for an injectable like Rejuran (whether as a device or biologic, depending on classification) is multi-year and capital-intensive. A successful US approval would dramatically re-rate the franchise globally because it would also serve as a gold-standard regulatory reference for other markets.
• Western Europe full coverage — current EU presence is selective; deeper penetration with country-by-country distributor agreements remains incremental upside.

The current revenue mix already meaningfully weights international, and the trajectory is toward further international over domestic as the Korean market matures and global clinic adoption scales.

6. Competitive Landscape — What Rejuran Is and Isn’t

Investors familiar with Korean aesthetics often try to map Rejuran against the more famous botulinum toxin and hyaluronic-acid filler names. The mapping is wrong, and getting the categorization right is essential to understanding the thesis.

Western analogues:

• Galderma’s Sunekos and the broader European polynucleotide / amino-acid skin-booster category — most directly comparable Western-market product class.
• Croma Pharma (Austria) — pipeline activity in PN / regenerative skin boosters.
• Some Italian PDRN brands (e.g., Mastelli) — more pharmaceutical-positioning than aesthetic-clinic positioning.
• Galderma’s Restylane Skinboosters (HA-based, different mechanism, but competing for the “skin quality” treatment slot in clinics).

Korean competitive entry

The Korean polynucleotide subcategory has begun to attract additional entrants attempting to compete with Rejuran on price or formulation differentiation. This is the most important medium-term competitive watch-point. PharmaResearch’s defensibility rests on:

1. Brand trust — Rejuran is the most-known PN brand in Korea, Southeast Asia, and significant parts of MENA.
2. Manufacturing quality — sterile injectable manufacturing under regulated quality systems is hard to replicate.
3. Clinical-channel relationships — KOL networks, training, clinic-loyalty programs.
4. Regulatory dossiers — international approvals are a multi-year asset that competitors cannot shortcut.

Bears point to PN as a category eventually being commoditized by multiple entrants, with margin compression following. Bulls point to brand-trust-led pricing power persisting in a clinic-channel-dependent category similar to how botulinum-toxin brands have historically held premium positioning despite molecular near-equivalence among entrants.

7. Investor Framework — Bull / Bear / Risks

Bull case

1. PN platform extensibility. Rejuran (face) → Conjuran (joint) → potential further indications → potential out-licensing.
2. International revenue runway. Korean market alone cannot grow at the trajectory observed; the international base is now meaningful and continues to expand by region.
3. China optionality. A successful regulated entry materially changes the franchise’s TAM math.
4. US optionality. A regulated US pathway, if achieved, is a global reference standard and a dramatic re-rating event.
5. Brand defensibility. Rejuran is one of the strongest aesthetic-injectable brands in Asia and is increasingly competitive globally.
6. K-aesthetics tailwind. Inbound medical tourism to Korea, Korean-clinic prestige globally, and K-beauty / K-pop cultural halos all support PharmaResearch’s brand premium.

Bear case

1. Single-flagship concentration. Rejuran (face) is a large share of revenue; any pricing or competitive event affecting the flagship hits the parent disproportionately.
2. Korean PN competition. New domestic entrants targeting Rejuran’s price point can compress margins faster than international growth offsets.
3. Regulatory friction. Any negative regulatory event in a major market — a label restriction, a competitor injection-quality issue spilling over to category sentiment, China NMPA scope changes — can stall momentum.
4. Western progress slow. US and broader EU regulatory pathways are slow and expensive; a multi-year delay against expectations would compress the long-term TAM math.
5. Counterfeit / parallel-import dilution. In high-demand markets like China and Vietnam, parallel-import and counterfeit risks affect both brand integrity and reported revenue.
6. Aesthetic-cycle macro. Discretionary aesthetic procedures are not recession-immune; severe global consumer-spending downturns affect clinic volumes.

Material risks to monitor

• Quarterly disclosure of Korea vs. ex-Korea revenue mix and major-region growth.
• China regulatory updates (NMPA approval scope, distributor configurations).
• US clinical / regulatory milestones if and when public.
• Margin trend — early signs of price competition in domestic Korean PN.
• Counterfeit / parallel-import disclosures in major Asian markets.
• Corporate-action / capital-allocation news (M&A, R&D in-licensing, possible spinout discussions).

8. Cross-Reference — How Rejuran / PharmaResearch Fits the Broader K-Aesthetics Stack

For investors building a K-aesthetics basket (rather than a single-name PharmaResearch position), the framework looks like this:

PharmaResearch occupies the regenerative injectable slot in this basket. It does not substitute for botulinum-toxin exposure or filler exposure; it complements them.

9. Final Read

The single-line answer to the search-engine query: Rejuran is owned by PharmaResearch Co., Ltd., listed on the Korean KOSDAQ as ticker 214450. There is no separate Rejuran ticker.

The investor-framing answer: Rejuran is the consumer face of a deeper asset — PharmaResearch’s PN / PDRN platform — which the company has converted into a global injectable franchise spanning Southeast Asia, the Middle East, Latin America, and selected European markets, with China and the US as the high-value pending catalysts.

The category-positioning answer: Rejuran is not a botulinum toxin and not a filler. It defines its own regenerative-skin-booster category, which makes it a portfolio-additive — not a portfolio-substitute — exposure within a K-aesthetics basket.

For global readers searching “who owns Rejuran” or “rejuran parent company,” the practical takeaway is that the brand and the parent are tightly linked, and the cleanest route to participate in the Rejuran growth story as an investor is to evaluate PharmaResearch (214450.KS) on its own platform-and-international-expansion merits.

Appendix — Evidence Tier

[Fact]

• Rejuran is a brand of polynucleotide-based skin-booster injectables.
• Rejuran is owned, manufactured, and globally licensed by PharmaResearch Co., Ltd.
• PharmaResearch is listed on the Korean KOSDAQ market under ticker 214450.
• PharmaResearch’s flagship platform is its PN (Polynucleotide) / PDRN technology, derived from purified salmon DNA.
• The Rejuran product family includes Rejuran Healer, Rejuran HB, Rejuran Eye, and Rejuran S, with additional SKUs and brand extensions in select markets.
• Conjuran is PharmaResearch’s PN-platform product for joint applications, distinct from Rejuran’s aesthetic/dermatologic positioning.
• Rejuran is distributed in many international markets via local distributors and clinic networks.
• Hugel, Medytox, and Daewoong Pharm are listed Korean botulinum-toxin players; PharmaResearch is not in the same category.
• Classys and Lutronic are listed Korean aesthetic-device companies adjacent to PharmaResearch’s clinic-channel ecosystem.

[Inference]

• PharmaResearch is currently the only listed public proxy for the polynucleotide skin-booster subcategory.
• PharmaResearch’s revenue trajectory has been increasingly driven by ex-Korea growth.
• Brand defensibility, manufacturing-quality reputation, and international regulatory dossiers create a meaningful moat against Korean PN entrants attempting price-led competition.
• China and US regulatory progress are the highest-value pending catalysts for the franchise.

[Speculation]

• A formal Rejuran spin-out is plausible but not currently announced; if it occurred, it would create a more direct public proxy.
• US FDA approval, if achieved, would likely act as a global reference standard and re-rate the franchise meaningfully across all markets.
• Korean PN competitive entrants will continue to increase, but Rejuran’s brand position and clinical-channel anchoring should sustain a premium for a multi-year horizon.

[Blocked]

• Exact most-recent quarterly Korea-vs-international revenue mix.
• Specific China NMPA approval scope and timeline.
• Specific US FDA pathway classification and milestone status.
• Detailed gross-margin breakdown by product line (Rejuran vs Conjuran vs cosmeceutical vs device).

Disclaimer: For research and information purposes only. Not investment advice. Names cited are for analytical illustration; readers should perform their own due diligence and consult licensed advisors before any investment decision.